Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | GNRHR | P30968 | 2/20 | 0.60 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | NPY4R | P50391 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 3/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497292 | 0.87 | AGTR2 (0.67) | AGTR2AGTR1GNRHRABCC2CXCR4 | |
| SCHEMBL29350127 | 0.87 | NTSR2 (0.63) | AGTR2AGTR1GNRHRABCC2CXCR4 | |
| SCHEMBL29627461 | 0.80 | TACR1 (0.60) | AGTR2AGTR1CXCR4NTSR2NTSR1 | |
| SCHEMBL30433133 | 0.80 | NPY1R (0.64) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29602731 | 0.80 | C5AR1 (0.63) | AGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL28485749 | 0.79 | AGTR2 (0.94) | AGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL29445593 | 0.79 | KISS1R (0.61) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31073544 | 0.79 | KISS1R (0.57) | NPY1RNPY2RNPY4RNPY5RREN | |
| SCHEMBL29619824 | 0.79 | AGTR2 (0.94) | AGTR2AGTR1 | |
| SCHEMBL7402113 | 0.79 | MAGI3 (0.56) | AGTR2AGTR1CXCR4NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4622962-A1 | SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING | The Board of Regents of the University of Texas System (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4511052-A2 | EPHRIN LIGAND MIMETIC PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | University of Miami (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042968-A1 | EPHRIN LIGAND MIMETIC PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV MIAMI (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024092083-A1 | SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023205752-A2 | EPHRIN LIGAND MIMETIC PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF MIAMI (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220251143-A1 | NON-HYDROLYZABLE NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | UNIV COLUMBIA (US) | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251143-A1 | NON-HYDROLYZABLE NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | SSTR4, SSTR1, SSTR5 | AGTR2 731/4885AGTR1 700/4885GNRHR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.